Идёт
Фаза I–II
ЭРДАФИТИНИБ и JNJ-63723283 · Janssen Pharmaceutica N.V., Belgium
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer